Twitter LinkedIn
    Monday, May 29
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Investments»TPG Sells More Than 10% of Novotech to Investors Ahead of IPO
    Investments

    TPG Sells More Than 10% of Novotech to Investors Ahead of IPO

    January 31, 2021Updated:January 31, 20212 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Private equity firm TPG is selling more than 10% of its clinical research and testing provider Novotech Pty Ltd to a group of investors.

    The transaction will value Novotech at more than $2.3 billion as the company prepares for an initial public offering in Hong Kong later this year, said Joel Thickins, head of Australia and New Zealand for TPG Capital Asia. He is also chairman of Novotech.

    The valuation makes the company one of the most successful investments for the private equity group in Asia, he said. The Sydney-based firm has increased revenues by more than 30% a year under TPG’s ownership since 2017, most recently helping with clinical trials for Covid-19 vaccines, as well as cancer and hepatitis drugs.

    “Novotech is a platform asset for us in Asia and a testament to the sector-led strategy we have pursued in differentiating ourselves from other sponsors,” Thickins said in an interview.

    He said TPG decided to invest in the clinical research industry in Asia in 2015 on intensifying investor demand for biotech companies and because the region’s populations were relatively untested in clinical trials compared with the U.S. and Europe. To be able to offer clinical testing services to health-care companies in the U.S. and Europe was a big opportunity for the firm.

    TPG also helped Novotech expand overseas. The company operates in 12 countries, with 70% of its revenue generated outside of Australia, compared with just 30% three years ago. It’s among the largest biotechnology contract research businesses across China, Southeast Asia, Taiwan and South Korea, which together make up a number of the fastest-growing markets for clinical trials.

    Anand Tharmaratnam will take over from Thickins as chairman of the company in April, the company said last month.

    Source: Bloomberg

     

    Image Source

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    Investments investors IPO
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Private equity firms Apollo and KKR among those reviewing Silicon Valley Bank loans

    March 16, 2023

    CAI raises over $1B for inaugural fund and co-investment programme

    November 18, 2022

    Carlyle launches renewable energy development platform Telis Energy in Europe

    November 15, 2022

    Partners Group buys data center platform EdgeCore Digital with $1.2B investment

    November 14, 2022

    Comments are closed.

    Other Articles

    Inter Milan close to €275m bailout by private equity firm Oaktree

    May 19, 2021

    Geely and Volvo to launch powertrain venture after merger scrapped

    February 27, 2021

    Rational bubble puts markets on high starting point for 2021

    January 2, 2021

    Private Equity Firm Aurora Capital Partners Acquires Grace Hill

    May 5, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?